JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Raf

Raf inhibitors act on A-Raf, B-Raf and C-Raf, serine/threonine kinases at the top of a growth factor kinase cascade. Activated by Ras, Raf kinases phosphorylate mitogen-activated protein kinase kinases (MEK1, MEK2), which then activate extracellular signal-regulated kinases (ERKs). In 2002 somatic mutations in BRAF, the gene encoding B-Raf, were reported in about two thirds of malignant melanomas. Structural work in 2004 showed that the most common mutation, now called V600E, activates B-Raf by disrupting its inactive conformation. Vemurafenib, dabrafenib, encorafenib and PLX-4720 preferentially inhibit B-Raf V600E, while TAK-632 inhibits all three Raf isoforms. Sorafenib tosylate blocks Raf kinases along with several receptor tyrosine kinases.

Cat. No.

A33462

CAS No.

150302-84-4

2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose

2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose functions as a selective binder for Fibroblast Growth Factor Receptor 3 (FGFR3) and BRAF, playing a pivotal role in modulating pathways associated with cancer progression. Derived from Atractylodes japonica, this compound exhibits low cytotoxicity towards cancer cell lines, making it a suitable candidate for research applications focused on targeted cancer therapies and signaling pathway studies. Its unique structural characteristics enhance its potential for further exploration in drug development and therapeutic interventions.

In stock View Details

5 mg

$605.00

All 1 sizes

Raf

2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose